Diuretics Compared: Loop, Thiazide, and Mineralocorticoid Antagonists
Executive Summary
Three diuretic classes anchor the management of volume overload and hypertension, each acting at a distinct nephron segment with predictable consequences for natriuresis, electrolyte handling, and outcome data. Loop diuretics (furosemide, torsemide, bumetanide) inhibit the Na/K/2Cl cotransporter in the thick ascending limb of Henle, where ~25% of filtered sodium is reabsorbed; they are the workhorse for acute decompensated heart failure, cirrhotic ascites, and renal failure. Thiazides (hydrochlorothiazide, chlorthalidone, indapamide, metolazone) inhibit the NCC cotransporter in the early distal convoluted tubule, where ~5–7% of filtered sodium is reabsorbed; they are the primary antihypertensive workhorse with chlorthalidone preferred over HCTZ on ALLHAT and SHEP outcome data. Mineralocorticoid receptor antagonists (spironolactone, eplerenone, finerenone) competitively block the aldosterone receptor in the late distal tubule and collecting duct; they have transformed heart failure outcomes in RALES (1999), EPHESUS (2003), EMPHASIS-HF (2011), and TOPCAT and now extend to chronic kidney disease in diabetes via FIDELIO-DKD and FIGARO-DKD with finerenone.
Sequential nephron blockade — combining a loop with a thiazide-like agent (most often metolazone or chlorthalidone) — overcomes diuretic resistance by attacking compensatory distal sodium reabsorption, but requires close electrolyte and renal monitoring with potassium frequently dropping ≥1 mEq/L within 48 hours. The choice between classes is driven by indication (HF/edema → loop; uncomplicated HTN → thiazide; HFrEF/PA/refractory HTN → MRA), eGFR (loops work below eGFR 30; thiazides progressively lose efficacy below eGFR 45), and combination strategy (MRAs added to loop+ACEi/ARNI in HFrEF; finerenone added to ACEi/ARB+SGLT2i in diabetic CKD).
S1 · Site of Action and Class Pharmacology
The nephron is the unit of diuretic action. Approximately 60–70% of filtered sodium is reabsorbed in the proximal tubule (carbonic anhydrase inhibitors act here, but contribute trivially to natriuresis), 25% in the thick ascending limb (the loop site), 5–7% in the early distal convoluted tubule (the thiazide site), and 2–5% in the late distal tubule and collecting duct (the MRA and ENaC blocker site). The fraction at each segment governs maximal natriuretic potency, but downstream segments compensate when an upstream segment is blocked — the central explanation for diuretic resistance and the rationale for sequential blockade.
Loop diuretics — Na/K/2Cl inhibition
Furosemide, torsemide, bumetanide, and ethacrynic acid bind the Na/K/2Cl cotransporter (NKCC2) at the apical membrane of the thick ascending limb. Blocking NKCC2 abolishes the medullary concentration gradient (urine becomes isosthenuric) and prevents the lumen-positive transepithelial voltage that drives paracellular Ca²⁺ and Mg²⁺ reabsorption — hence the characteristic urinary calcium and magnesium losses. Loops require active tubular secretion via the OAT3 transporter to reach their luminal site of action; uremic anions, NSAIDs, and probenecid compete and reduce delivery.
Thiazides — NCC inhibition
Hydrochlorothiazide, chlorthalidone, indapamide, and metolazone bind the Na-Cl cotransporter (NCC) in the early distal convoluted tubule. Maximum natriuretic effect is modest (~5% of filtered Na) but the reduced distal sodium delivery shifts the basolateral Na/Ca exchanger toward calcium reabsorption — explaining the calcium-sparing effect (useful in osteoporosis, harmful in hypercalcemia). Thiazides require glomerular filtration to reach their luminal target; below eGFR ~30, urinary delivery falls and natriuretic efficacy collapses (with the notable exception of metolazone, which retains some activity at low eGFR).
Mineralocorticoid receptor antagonists — aldosterone blockade
Spironolactone is a non-selective steroidal MRA that also binds androgen and progesterone receptors (hence gynecomastia, menstrual irregularities). Eplerenone is a selective steroidal MRA with ~25% the receptor affinity of spironolactone but markedly fewer endocrine side effects. Finerenone is a non-steroidal MRA with high MR selectivity, balanced renal-cardiac distribution, and a distinct binding mode that confers shorter half-life and less hyperkalemia at equipotent doses — a profile validated for diabetic CKD in FIDELIO-DKD and FIGARO-DKD.
| Class | Site | Transporter | Max natriuresis | Calcium handling |
|---|---|---|---|---|
| Loop | Thick ascending limb | NKCC2 | 20–25% of filtered Na | Hypercalciuria |
| Thiazide | Early distal tubule | NCC | 5–7% | Hypocalciuria (Ca-sparing) |
| MRA | Late distal/collecting duct | ENaC (indirectly) | 2–3% | Neutral |
| K+-sparing (amiloride) | Late distal/collecting duct | ENaC (direct) | 2–3% | Neutral |
| Carbonic anhydrase inhibitor | Proximal tubule | NHE3 (indirectly) | 2–4% | Hypercalciuria, alkaline urine |
S2 · Loop Diuretics — Agents and Dosing
Furosemide (Lasix) — most prescribed, least bioavailable
The reference loop diuretic. Oral bioavailability is highly variable (10–90%, mean 50%) and worsens further in decompensated heart failure due to gut wall edema and delayed absorption. The 1:2 IV-to-PO conversion (e.g., 40 mg IV ≈ 80 mg PO) is a clinical rule of thumb, though individualization is essential. Onset 30–60 min PO, 5 min IV; duration 6 hours; renal elimination of 50% unchanged drug.
Furosemide 20–40 mg PO daily is the typical starting outpatient dose for hypertension or mild edema. 40–80 mg IV bolus q12h is reasonable for acute decompensated heart failure in a diuretic-naïve patient; for chronic loop users, the parenteral dose should equal or exceed 1× the total daily home oral dose. 5–10 mg/hr IV continuous infusion (after 40–80 mg IV bolus) is preferred over high intermittent boluses in DOSE trial substudies for refractory cases, though primary endpoint of the DOSE trial showed no advantage in 72-hour weight loss.
Torsemide (Demadex) — TRANSFORM-HF data
Higher and more predictable oral bioavailability (80–100%) and longer half-life (3–4 hours vs furosemide 1.5 hours). The TRANSFORM-HF trial (2023, JAMA, 2,859 HF patients post-discharge) randomized torsemide vs furosemide — no significant difference in 12-month all-cause mortality (HR 1.02). Despite earlier observational suggestions of torsemide superiority, the trial result has shifted opinion toward furosemide as first-line with torsemide reserved for documented absorption failure or persistent edema. Torsemide 10–20 mg PO daily; equivalent to furosemide 40 mg PO. IV-to-PO ratio approximately 1:1.
Bumetanide (Bumex) — most potent on a per-mg basis
Bioavailability 80–100%, half-life 1–1.5 hours, 40× more potent than furosemide on a milligram basis (1 mg bumetanide ≈ 40 mg furosemide). Used when oral furosemide absorption is questionable. Bumetanide 0.5–1 mg PO daily–BID; 0.5–1 mg IV q8–12h for acute care. Myalgia is a notable bumetanide-specific adverse effect at higher doses.
Ethacrynic acid (Edecrin) — sulfa-allergy alternative
The only non-sulfonamide loop diuretic; preserved as an option in patients with documented sulfa allergy. Greater ototoxicity than other loops, especially with rapid IV administration. Ethacrynic acid 50 mg IV ≈ furosemide 40 mg IV.
Renal dose adjustment
Loop diuretics retain efficacy across the eGFR spectrum, but at low eGFR (<30) higher doses are required to achieve the same urinary drug delivery — the "ceiling dose" rises proportionally. A patient with eGFR 20 may require furosemide 160–200 mg IV bolus to achieve the same natriuresis as 40 mg IV in a patient with normal renal function. Maximum single doses of furosemide ~200 mg IV (over 30+ min infusion to avoid ototoxicity), torsemide 200 mg, bumetanide 10 mg.
| Drug | Equivalent dose (PO) | Bioavailability | Half-life | Best use |
|---|---|---|---|---|
| Furosemide | 40 mg | 10–90% (variable) | 1.5 h | First-line, low cost |
| Torsemide | 20 mg | 80–100% | 3–4 h | Reliable PO absorption |
| Bumetanide | 1 mg | 80–100% | 1–1.5 h | When oral furosemide fails |
| Ethacrynic acid | 50 mg | ~100% | 2–4 h | Sulfa allergy |
S3 · Thiazides — When and Which Agent
Chlorthalidone — guideline-preferred for hypertension
SHEP, ALLHAT, and the MRFIT meta-analyses all used chlorthalidone, not HCTZ. Pharmacokinetically, chlorthalidone has a much longer half-life (~40–60 hours vs HCTZ ~6–15 hours) and provides smoother 24-hour blood pressure control with greater nocturnal dipping and less morning surge. ACC/AHA 2017 hypertension guidelines specifically prefer chlorthalidone over HCTZ when a thiazide is selected. Chlorthalidone 12.5 mg PO daily is the typical starting dose, titrated to 25 mg daily; doses ≥50 mg add little efficacy and double the rate of hypokalemia.
Hydrochlorothiazide (HCTZ) — most prescribed by inertia
Despite weaker outcome data versus chlorthalidone, HCTZ remains the most prescribed thiazide globally because of its century of use, low cost, and inclusion in countless fixed-dose combination tablets. HCTZ 12.5–25 mg PO daily is standard; doses above 25 mg are discouraged because of the steeply rising hypokalemia risk without commensurate BP benefit. The Hennepin County study and MRFIT extension hint at modestly inferior cardiovascular outcomes versus chlorthalidone at typical doses.
Indapamide — favored in some guidelines (ESC/ESH)
Indapamide has additional vasodilatory properties beyond pure thiazide action. The HYVET trial used indapamide SR 1.5 mg PO daily in very-elderly hypertensive patients (age ≥80) and demonstrated 30% stroke reduction. ESC/ESH 2023 lists indapamide as a preferred thiazide-like agent.
Metolazone (Zaroxolyn) — sequential blockade workhorse
A long-acting thiazide-like diuretic uniquely useful at low eGFR because its lipid solubility and partial proximal-tubule action persist below eGFR 30. Metolazone 2.5–5 mg PO daily 30 minutes before a loop diuretic dose produces dramatic, sometimes excessive, natriuresis. Standard practice: start metolazone every 2–3 days, not daily, with K+ checked at 48 hours; daily metolazone in HF can drop serum K+ by 1.5 mEq/L within a week.
| Drug | Half-life | Typical dose | Outcome data | Comments |
|---|---|---|---|---|
| Chlorthalidone | 40–60 h | 12.5–25 mg PO daily | SHEP, ALLHAT | Guideline-preferred |
| HCTZ | 6–15 h | 12.5–25 mg PO daily | Limited monotherapy outcome data | Common, but inferior to chlorthalidone |
| Indapamide SR | 14–18 h | 1.5 mg PO daily | HYVET (very elderly) | Vasodilator + thiazide |
| Metolazone | 14 h | 2.5–5 mg PO every 2–3 days | Used in DOSE trial substudies | Works at eGFR <30; sequential blockade |
S4 · Mineralocorticoid Receptor Antagonists
Spironolactone — the original MRA
Non-selective steroidal MRA with cross-binding at androgen and progesterone receptors. RALES (1999, NEJM) randomized 1,663 NYHA III–IV HFrEF patients to spironolactone 25 mg PO daily vs placebo on background ACEi/loop; 30% relative reduction in all-cause mortality (35% vs 46% at 24 months) led to early termination. Subsequent indications include primary hyperaldosteronism, hepatic cirrhosis with ascites (spironolactone 100–400 mg PO daily titrated against natriuresis, often paired with furosemide in 100:40 mg ratio), and resistant hypertension. PATHWAY-2 (2015, Lancet) established spironolactone 25–50 mg PO daily as the most effective fourth-line drug for resistant hypertension, superior to bisoprolol and doxazosin. Adverse effects: gynecomastia (~10% of men at 50 mg, dose-dependent), menstrual irregularity, decreased libido, hyperkalemia.
Eplerenone — selective, fewer endocrine effects
EPHESUS (2003, NEJM) randomized 6,632 post-MI patients with EF ≤40% and HF to eplerenone 25 mg PO daily titrated to 50 mg vs placebo; 15% relative reduction in all-cause mortality. EMPHASIS-HF (2011, NEJM) extended benefit to NYHA II HFrEF patients (EF ≤35%): 24% mortality reduction, 37% reduction in HF hospitalization. Eplerenone has ~40-fold lower androgen receptor affinity than spironolactone, hence dramatically less gynecomastia (~1%). Cost remains higher than spironolactone in many markets.
Finerenone — non-steroidal MRA for diabetic CKD
FIDELIO-DKD (2020, NEJM, n=5,734 diabetic CKD UACR 30–5,000) and FIGARO-DKD (2021, NEJM, n=7,437) randomized finerenone 10–20 mg PO daily vs placebo on top of maximally tolerated ACEi/ARB. FIDELIO showed 18% reduction in renal composite (kidney failure, sustained ≥40% eGFR decline, renal death). FIGARO showed 13% reduction in cardiovascular composite. The FIDELITY pre-specified pooled analysis: 14% reduction in MACE, 23% reduction in HF hospitalization. Hyperkalemia rate was substantially lower than with steroidal MRAs at equivalent renal protection. Finerenone is now a Level 1A recommendation in KDIGO 2024 for diabetic CKD with albuminuria, layered on ACEi/ARB and SGLT2 inhibitor.
TOPCAT — controversial HFpEF data
TOPCAT (2014, NEJM, n=3,445 HFpEF EF ≥45%) of spironolactone 30 mg PO daily titrated to 45 mg showed no significant primary endpoint reduction. The pre-specified Americas-only sensitivity analysis demonstrated 18% reduction in CV death/HF hospitalization, prompting many guidelines to give a IIb recommendation for spironolactone in HFpEF — though the trial’s geographic discrepancy and quality concerns about Russian/Georgian sites kept it from a stronger recommendation.
| MRA | Selectivity | Half-life | Trial evidence | Class effect |
|---|---|---|---|---|
| Spironolactone | Non-selective (binds AR, PR) | ~13 h (active metabolites longer) | RALES (HFrEF), PATHWAY-2 (HTN) | Cheap, gynecomastia common |
| Eplerenone | Selective steroidal | 4–6 h | EPHESUS, EMPHASIS-HF | Less endocrine effects, costlier |
| Finerenone | Non-steroidal, highly selective | 2–3 h | FIDELIO-DKD, FIGARO-DKD | Lower hyperkalemia at equipotent dose |
S5 · Sequential Nephron Blockade and Diuretic Resistance
Why diuretic resistance develops
Chronic loop diuretic exposure produces hypertrophy of distal tubule cells (Ellison, 1989) and upregulation of NCC, ENaC, and Na/K ATPase activity. Even brief blockade of upstream NKCC2 results in compensatory distal sodium reabsorption that progressively neutralizes the natriuretic effect — the “braking phenomenon.” Add to this gut wall edema reducing oral bioavailability, neurohormonal activation (renin, aldosterone, sympathetic tone) driving sodium avidity, and hypoalbuminemia reducing tubular drug delivery, and the patient with chronic HF or cirrhosis can require quintupling the loop dose for the same urine output.
Step-up algorithm for loop diuretic resistance
- Confirm adherence and salt restriction (<2 g sodium daily); spot urine Na+ <25 mEq/L during acute decongestion confirms loop ineffectiveness
- Optimize the loop: switch from PO to IV; double the dose; convert intermittent bolus to continuous infusion (5–10 mg/hr furosemide after loading bolus)
- Add a thiazide-like agent: Metolazone 2.5–5 mg PO 30 min before loop dose, or Chlorthalidone 25 mg PO daily, or HCTZ 25 mg PO daily
- Add an MRA: Spironolactone 25–50 mg PO daily contributes natriuresis, particularly in cirrhotic ascites
- Consider acetazolamide for metabolic alkalosis: Acetazolamide 250–500 mg IV daily × 2–3 days; the ADVOR trial (2022, NEJM) showed acetazolamide added to IV loop in acute HF improved decongestion at 3 days (42% vs 31%)
- SGLT2 inhibitor for HF: Dapagliflozin 10 mg PO daily or empagliflozin 10 mg PO daily contributes glucosuric osmotic diuresis (~300–400 mL/day) and improves long-term outcomes
- Ultrafiltration: reserve for true diuretic refractoriness; CARRESS-HF (2012) showed equivalent outcomes to stepped pharmacologic care with worse renal function
| Combination | Mechanism | Typical dose | Caution |
|---|---|---|---|
| Loop + thiazide-like (sequential blockade) | Block proximal + distal Na reabsorption | Furosemide 80 mg + Metolazone 5 mg | K+ drop ≥1 mEq within 48h |
| Loop + MRA | Add aldosterone blockade | Furosemide 40 mg + Spironolactone 25 mg | Hyperkalemia in CKD |
| Loop + SGLT2i | Osmotic glucose-driven diuresis | Furosemide + Dapagliflozin 10 mg | Volume depletion if over-diuresed; HFrEF/HFpEF benefit |
| Loop + acetazolamide | Block proximal Na reabsorption; correct met. alkalosis | Furosemide IV + Acetazolamide 500 mg IV | Worsens metabolic acidosis; ADVOR data |
| Triple (loop + thiazide + MRA) | Block multiple segments | Reserved for refractory cases | Frequent K+, Mg+, Cr monitoring (q24–48h) |
S6 · Adverse Effects, Drug Interactions, and FAQ
Adverse-effect profile by class
| Adverse effect | Loop | Thiazide | MRA |
|---|---|---|---|
| Hypokalemia | +++ | +++ | — (causes hyperK) |
| Hyperkalemia | — | — | +++ |
| Hypomagnesemia | +++ | ++ | + (less) |
| Hyponatremia | ++ (less than thiazide) | +++ (esp. elderly women) | + |
| Hyperuricemia / gout | ++ | ++ | — |
| Hyperglycemia | + | ++ | — |
| Hyperlipidemia | + | + | — |
| Hypocalcemia | ++ (urinary Ca loss) | — (calcium-sparing) | — |
| Ototoxicity | ++ (rapid IV bolus) | — | — |
| Photosensitive rash | + (sulfa) | + (sulfa) | — |
| Gynecomastia | — | — | +++ spironolactone, + eplerenone |
Critical drug interactions
- NSAIDs: blunt all diuretic classes by reducing renal prostaglandin-mediated vasodilation; reduce diuretic efficacy by 30–50% and accelerate AKI when combined with ACEi/ARB (“triple whammy”)
- Lithium: thiazides and (to a lesser degree) loops increase serum lithium concentration by reducing distal sodium delivery; lithium toxicity can develop within days
- Aminoglycosides: synergize loop diuretic ototoxicity dramatically
- Digoxin: diuretic-induced hypokalemia and hypomagnesemia precipitate digoxin toxicity
- Trimethoprim, ACEi/ARB, K+-sparing diuretics: compound MRA-induced hyperkalemia; check K+ within days when combined
- CYP3A4 inhibitors (ketoconazole, clarithromycin): increase eplerenone and finerenone exposure; eplerenone contraindicated with strong CYP3A4 inhibitors, finerenone dose reduced
Monitoring schedule
For new diuretic initiation: BMP at 1–2 weeks, then 1 month, then quarterly when stable. After dose increase: BMP within 1–2 weeks. After adding MRA or sequential blockade: K+, Mg+, Cr at 48 hours, 1 week, 1 month. Outpatient HF on triple therapy (loop + ACEi/ARNI + MRA): BMP every 1–3 months.
FAQ
S7. Practice Insights: Diuretic Dosing That Actually Works
1. Find the Loop Ceiling Dose First
In experienced practice, every patient with apparent loop diuretic “resistance” first gets a documented ceiling dose test. Furosemide doubles from 40 mg PO until natriuresis (or until 200-240 mg PO single dose). In CKD with eGFR <30 the effective single dose is typically 80-160 mg PO, and most clinicians underdose because they “don’t want to push it.” Bumetanide 1 mg IV is equivalent to furosemide 40 mg IV and to torsemide 20 mg PO — clinicians use this conversion explicitly to keep dosing consistent across forms. The bioavailability of PO furosemide is only ~50% (and erratic in gut edema), so IV doses look smaller but are functionally larger.
2. Chlorthalidone Over HCTZ
In experienced hands, chlorthalidone 12.5-25 mg daily replaces hydrochlorothiazide for nearly every hypertension and sequential-blockade indication. Chlorthalidone has a half-life of 40-60 hours (vs 6-15 for HCTZ), provides 24-hour BP control on a single morning dose, and was the diuretic used in ALLHAT, SHEP, and most outcomes trials demonstrating cardiovascular benefit. HCTZ at typical doses (12.5-25 mg) has weaker outcomes data and substantially shorter duration. The metabolic profile is similar between the two. Combination chlorthalidone formulations exist and the long-acting effect is worth the prescription effort.
3. Sequential Blockade: Thiazide BEFORE Loop
Routinely, when a patient is failing on ceiling-dose loop diuretic, clinicians add metolazone 2.5-5 mg or chlorthalidone 25 mg dosed 30-60 minutes BEFORE the loop diuretic, not after. The mechanistic rationale is that the loop diuretic delivers extra sodium to the distal tubule where thiazide-sensitive transporters are; if the distal tubule receptor is already blocked when the loop kicks in, sequential blockade works. Dosing the thiazide hours after the loop wave has already passed misses the synergy window. Clinicians check daily K+ and Mg+ when running sequential blockade because the natriuresis is brisk.
4. MRA: Start Low, Check K+, Up-Titrate
In experienced hands, spironolactone starts at 12.5-25 mg daily, with serum K+ and Cr checked at 1 week and 1 month, and titrated to 50 mg daily if tolerated for HFrEF or resistant HTN. The patients who get into trouble with MRA hyperkalemia almost always have eGFR <30 at start or were never re-checked after initiation. Clinicians document an explicit K+ recheck plan in the chart at the time of MRA prescription — and clinicians use the EMR forcing function to flag K+ >5.5 as a stop-and-reassess alert. For male patients with breast tenderness or gynecomastia on spironolactone, experienced practitioners switch to eplerenone 25-50 mg daily with same monitoring. Finerenone is a newer non-steroidal MRA with stronger cardiorenal evidence in diabetic CKD that clinicians use increasingly in that population.
Illustrative Scenario: The “Diuretic-Resistant” HFrEF Who Just Needed More Loop
A middle-aged man with HFrEF (EF 20%) was admitted for his third volume overload exacerbation in 6 months. His outpatient regimen was furosemide 40 mg PO daily, spironolactone 12.5 mg daily, and chlorthalidone had been tried briefly and stopped because of “no response.” On admission he was 8 kg above dry weight with peripheral edema to the thighs, abdominal distension, and JVP at the angle of the jaw. Baseline Cr was 1.4, eGFR 52, K+ 4.3.
On the consult the treating clinicians had him take a single furosemide 80 mg IV dose and measured urine output over the next 6 hours. He produced only 600 mL. Clinicians escalated to furosemide 160 mg IV, which produced 2.4 L over 6 hours. They then added metolazone 5 mg PO dosed 30 minutes before each furosemide dose, K+/Mg+ replacement, and titrated spironolactone to 25 mg with K+ check at 5 days. He lost 7 kg over 4 days without renal injury, K+ remained 4.1-4.5, and was discharged on furosemide 80 mg PO BID + metolazone 2.5 mg before morning dose + spironolactone 25 mg. Two-month follow-up: 4.5 kg below previous “dry weight,” no readmission.
Practice Pattern Refinements vs Standard Approach
- Loop ceiling-dose test first. Furosemide doubled to 80, 160, 240 mg until natriuresis. CKD needs higher doses. Bumetanide 1 mg = furosemide 40 mg IV = torsemide 20 mg PO.
- Chlorthalidone > HCTZ for HTN and sequential blockade. 40-60 hr half-life, ALLHAT outcomes data. Combination pills exist; prescribe them.
- Sequential blockade: thiazide 30-60 min BEFORE loop diuretic, not after. Synergy window matters. Daily K+/Mg+ surveillance.
- MRA start 12.5-25 mg + K+ check at 1 wk and 1 mo; titrate to 50 mg if tolerated. Eplerenone for gynecomastia; finerenone for diabetic CKD.
- Antiviral Therapy for Herpesviruses: Acyclovir, Valacyclovir, Ganciclovir, Foscarnet
- Antipseudomonal Beta-Lactams: Piperacillin-Tazobactam, Cefepime, Ceftazidime, Meropenem, and Ceftolozane-Tazobactam in Practice
- Fluoroquinolones: Black Box Risks, Restricted Indications, and Appropriate Use
- Sacubitril-Valsartan (ARNI): Initiation, Titration, and Monitoring in HFrEF
- Vonoprazan vs PPIs: PCAB Pharmacology, Pivotal Trial Evidence, and Clinical Use
- IL-23 Inhibitors: Risankizumab, Guselkumab, Tildrakizumab in Psoriasis, PsA, and IBD